Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Madrigal granted 9,642 restricted stock units to 26 new employees
- ➤Awards vest in four equal annual installments, subject to continued employment
- ➤Rezdiffra is approved for MASH with moderate to advanced fibrosis (F2 to F3)
- ➤Phase 3 trial is evaluating Rezdiffra in compensated MASH cirrhosis (F4c)
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 9,642 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
Get started
Create a free account to read the full story.